10x Genomics Launches Autoimmune Biomarker Research Collaborations

The new partnerships with Charité and DRFZ in Berlin and with Seoul National University's Genomic Medicine Institute focus on blood-based biomarkers.

Updated on Nov. 17, 2026 in Biotech

Bold flat-color editorial illustration of amber sample vials in a grid with luminous cell clusters, illustrating blood-based autoimmune research.
10x Genomics announced two new blood-based biomarker research collaborations for autoimmune disease with Charité and DRFZ in Berlin and Seoul National University's Genomic Medicine Institute. AI Illustration. Upload story photo >

10x Genomics announced two new research collaborations on blood-based biomarkers for autoimmune disease. One involves Charité and DRFZ in Berlin, and the other involves Seoul National University's Genomic Medicine Institute.

Why it matters

The collaborations aim to identify biomarkers of disease activity and treatment response in autoimmune conditions. They also explore how findings could inform future reporting frameworks for disease monitoring and treatment planning.

The Charité and DRFZ study plans to enroll 750 patients over several years, while the Seoul National University collaboration focuses on alopecia areata using cohorts from the SCAID program, which was launched in 2022. Findings from either study have not yet been reported.

The players

10x Genomics

A Pleasanton, California-based life sciences company listed on Nasdaq under the symbol TXG, known for single-cell and spatial biology tools.

Charité

A major academic medical center in Berlin that is one of Europe's largest university hospitals.

Seoul National University

A leading public research university in Seoul, South Korea, home to its Genomic Medicine Institute.

The details

Both collaborations plan to use Flex Apex to analyze longitudinal blood samples at single-cell resolution. The Berlin study will follow patients starting or adjusting biologic or targeted therapies, with blood collected during routine clinical visits.

Timeline

  1. Earlier in 2026: 10x Genomics outlined a clinical strategy focused on single-cell diagnostics.

  2. November 16, 2026: 10x Genomics announced the two new research collaborations.

  3. Multi-year: The Charité and DRFZ study of 750 patients is planned to run.

Roadmap

The collaborations build on SCAID, a 2022 research program that mapped immune-mediated diseases at single-cell level. They extend that work into longitudinal blood monitoring and mirror 10x Genomics' earlier 2026 push toward oncology and autoimmune clinical applications.

If the research succeeds, patients with autoimmune conditions could eventually benefit from blood tests that track disease activity and predict treatment response. Patients in these studies would have blood drawn during routine clinical visits rather than through separate procedures.

The takeaway

Blood-based single-cell tools may eventually help clinicians tailor autoimmune treatments more precisely. Progress will depend on whether early research findings hold up in larger clinical settings.

Further reading

Explore more developments in Biotech research and diagnostics.

Source note: This article includes information reported by The Independent Record.